METHODS	In this randomised , double-blind , placebo-controlled multicenter study , adults with NYHA class II or III CHF and reduced left ventricular ejection fraction ( LVEF < or = 35 % ) were included and received 900 mg/day WS 1442 or placebo for 24 months .\